Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio, Inc. filed an Initial Statement of Beneficial Ownership (Form 3) for director Stephen Hui Wang relating to an event on 07/25/2025. The filing states that no securities are beneficially owned by the reporting person. The Form 3 was executed via Power of Attorney and signed by Erin Butler, Attorney-in-Fact on 10/10/2025. The filing notes it was submitted late due to delays obtaining the reporting person’s EDGAR codes.
ImageneBio, Inc. completed a reverse recapitalization through a merger with Ikena Oncology that resulted in ImageneBio as the public company and produced pro forma combined financial statements giving effect as if the transactions occurred on January 1, 2024. The company divested its Non-OX40 business to SellCo for a promissory note of $8.9 million that accrues interest at 4.61% and matures by 2035 or on earlier default triggers. The filing highlights one-time pro forma adjustments including $14.9 million of share-based compensation, other merger-related cash payments (severance/retention and D&O tail) and derecognition of certain deferred offering costs. Management warns of recurring losses and negative operating cash flows that raise substantial doubt about going concern and states additional capital will be required to advance IMG-007.
IMG-007 is a non-depleting anti-OX40 monoclonal antibody in Phase 2 development for moderate-to-severe atopic dermatitis. Clinical results disclosed include a Phase 1b/2a proof-of-concept with durable activity up to 24 weeks, an EASI-75 rate of 54% by Week 16 in a 13-patient cohort, favorable tolerability (no serious adverse events reported), target-mediated PK with projected therapeutic IV doses (300–600 mg) maintaining target levels for 18 weeks and mean terminal half-life ~31–35 days. The company discloses patent filings (U.S. and international) with expected patent expiration in 2041 and notes regulatory, manufacturing, intellectual property, litigation and reimbursement risks.
ImageneBio insider ownership updated after a corporate merger. The Form 4 reports that, as part of a two-step merger, legacy Inmagene ordinary and preferred shares were converted into Issuer common stock at a fixed exchange ratio, resulting in the reporting person receiving 143,832 shares directly and an indirect interest in 971,173 shares held by Engene Inc.
The transfers arose from the merger consideration exchanged for 47,142,857 Series Seed convertible preferred shares and 318,313,306 ordinary shares of legacy Inmagene, using a conversion factor of 0.003051 common shares per legacy share. The filer disclaims beneficial ownership of Engene Inc.'s shares except for any pecuniary interest; Engene Inc.'s sole shareholder is a trust for which reporting person's family are beneficiaries. The filing notes it was submitted late due to administrative delays.
ImageneBio, Inc. director Jonathan Jian Wang submitted an initial Form 3 reporting no securities beneficially owned as of the event date 07/25/2025. The filing notes it was submitted late because the reporting person experienced delays obtaining EDGAR access codes; the form is signed by an attorney-in-fact on 08/15/2025. No non-derivative or derivative holdings are disclosed.
ImageneBio amended its current report to provide additional disclosure about the acquired business, Inmagene. The amendment adds Management's Discussion and Analysis for Inmagene and unaudited interim condensed financial statements covering the three- and six-month periods ended June 30, 2025 and 2024. The filing incorporates these items as Exhibits 99.3 and 99.4 and states it does not change any other previously reported items or discuss developments after the original report. The disclosure supplements the Original Report that had reported completion of the Merger.